KR101452792B1 - 펙소페나딘 현탁액 제형 - Google Patents

펙소페나딘 현탁액 제형 Download PDF

Info

Publication number
KR101452792B1
KR101452792B1 KR1020087014471A KR20087014471A KR101452792B1 KR 101452792 B1 KR101452792 B1 KR 101452792B1 KR 1020087014471 A KR1020087014471 A KR 1020087014471A KR 20087014471 A KR20087014471 A KR 20087014471A KR 101452792 B1 KR101452792 B1 KR 101452792B1
Authority
KR
South Korea
Prior art keywords
aqueous pharmaceutical
volume
weight
pharmaceutical suspension
sodium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087014471A
Other languages
English (en)
Korean (ko)
Other versions
KR20080074180A (ko
Inventor
프라풀라 아그라왈라
카지미에르즈 크르잔
라지브 하리브학티
매튜 머메이
커티스 제이. 포첼로
개리 리 실베이
빈 트란
Original Assignee
사노피-아벤티스 유.에스. 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38120312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101452792(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 사노피-아벤티스 유.에스. 엘엘씨 filed Critical 사노피-아벤티스 유.에스. 엘엘씨
Publication of KR20080074180A publication Critical patent/KR20080074180A/ko
Application granted granted Critical
Publication of KR101452792B1 publication Critical patent/KR101452792B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
KR1020087014471A 2005-12-14 2006-12-12 펙소페나딘 현탁액 제형 Expired - Fee Related KR101452792B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75030305P 2005-12-14 2005-12-14
US60/750,303 2005-12-14
PCT/US2006/047393 WO2007070517A2 (en) 2005-12-14 2006-12-12 Fexofenadine suspension formulation

Publications (2)

Publication Number Publication Date
KR20080074180A KR20080074180A (ko) 2008-08-12
KR101452792B1 true KR101452792B1 (ko) 2014-10-22

Family

ID=38120312

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087014471A Expired - Fee Related KR101452792B1 (ko) 2005-12-14 2006-12-12 펙소페나딘 현탁액 제형

Country Status (38)

Country Link
US (1) US8933097B2 (https=)
EP (1) EP1965768B1 (https=)
JP (1) JP5308824B2 (https=)
KR (1) KR101452792B1 (https=)
CN (1) CN101316580B (https=)
AR (1) AR058323A1 (https=)
AT (1) ATE431137T1 (https=)
AU (1) AU2006326551B2 (https=)
BR (1) BRPI0619895B1 (https=)
CA (1) CA2633086C (https=)
CR (1) CR9993A (https=)
CY (1) CY1109320T1 (https=)
DE (1) DE602006006870D1 (https=)
DK (1) DK1965768T3 (https=)
DO (1) DOP2006000274A (https=)
EC (1) ECSP088532A (https=)
EG (1) EG25866A (https=)
ES (1) ES2327168T3 (https=)
HN (1) HN2008000875A (https=)
HR (1) HRP20090411T1 (https=)
IL (1) IL192067A (https=)
JO (1) JO2549B1 (https=)
MA (1) MA30152B1 (https=)
MY (1) MY146988A (https=)
NO (1) NO339877B1 (https=)
NZ (1) NZ568943A (https=)
PE (1) PE20071003A1 (https=)
PL (1) PL1965768T3 (https=)
PT (1) PT1965768E (https=)
RS (1) RS51135B (https=)
RU (1) RU2405538C2 (https=)
SI (1) SI1965768T1 (https=)
TN (1) TNSN08186A1 (https=)
TW (1) TWI377061B (https=)
UA (1) UA89584C2 (https=)
UY (1) UY30021A1 (https=)
WO (1) WO2007070517A2 (https=)
ZA (1) ZA200803985B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546774B1 (ko) 2008-07-29 2015-08-24 엘지전자 주식회사 휴대 단말기 및 그 동작제어 방법
CA2852447A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
US10130620B2 (en) 2013-07-01 2018-11-20 Aventisub Llc Liquid pharmaceutical composition for oral administration comprising fexofenadine
BR112015032791A2 (pt) * 2013-07-03 2017-07-25 Scherer Technologies Llc R P composição para uso como enchimento de cápsula, e, cápsula
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
CN106806346B (zh) * 2015-12-01 2020-09-11 国药集团广东环球制药有限公司 一种非索非那定盐酸盐干混悬剂制剂及其制备方法
ES3014923T3 (en) 2016-06-16 2025-04-28 Azurity Pharmaceuticals Inc Composition and method for proton pump inhibitor suspension
EP3639812A4 (en) 2017-06-02 2021-03-17 Teika Pharmaceutical Co., Ltd. SOLUBILIZED MICELLA CONSISTING OF A LOW SOLUBLE COMPONENT AND SOLUTION CONTAINING IT
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
EP4199980A1 (en) * 2020-08-18 2023-06-28 Innate S.r.l. Injectable composition and use of said composition
WO2022175829A1 (en) 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
AU2021480621A1 (en) * 2021-12-29 2024-07-18 Opella Healthcare Group Sas Compositions containing fexofenadine
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法
EP4651852A1 (en) 2023-01-20 2025-11-26 Opella Healthcare Group SAS Paraben-free fexofenadine formulations
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066974A1 (en) 2003-01-30 2004-08-12 Ethypharm Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
CN1148849A (zh) * 1994-05-18 1997-04-30 赫彻斯特马里恩鲁斯公司 抗组胺哌啶衍生物，其多晶形物和假同晶物的无水和水合物形式的制备方法
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
WO2003011295A1 (en) 2001-07-31 2003-02-13 Texcontor Etablissement Fexofenadine polymorph
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
DK2377557T3 (en) * 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
CN101228128A (zh) 2005-07-27 2008-07-23 桑多斯股份公司 一种用于制备取代苯基醚化合物和罗西格列酮的方法
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066974A1 (en) 2003-01-30 2004-08-12 Ethypharm Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles

Also Published As

Publication number Publication date
PT1965768E (pt) 2009-08-07
PE20071003A1 (es) 2007-10-03
DK1965768T3 (da) 2009-09-07
WO2007070517A2 (en) 2007-06-21
UY30021A1 (es) 2007-07-31
DOP2006000274A (es) 2007-10-15
JP5308824B2 (ja) 2013-10-09
JP2009519935A (ja) 2009-05-21
HN2008000875A (es) 2012-01-30
UA89584C2 (en) 2010-02-10
TW200812581A (en) 2008-03-16
IL192067A0 (en) 2009-02-11
DE602006006870D1 (de) 2009-06-25
NZ568943A (en) 2010-04-30
US20080299211A1 (en) 2008-12-04
CA2633086A1 (en) 2007-06-21
ES2327168T3 (es) 2009-10-26
ATE431137T1 (de) 2009-05-15
MY146988A (en) 2012-10-15
RU2405538C2 (ru) 2010-12-10
BRPI0619895B1 (pt) 2022-04-12
SI1965768T1 (sl) 2009-10-31
WO2007070517A3 (en) 2007-08-23
TNSN08186A1 (en) 2009-10-30
CA2633086C (en) 2011-10-18
CN101316580B (zh) 2011-11-16
ZA200803985B (en) 2009-03-25
CN101316580A (zh) 2008-12-03
RS51135B (sr) 2010-10-31
TWI377061B (en) 2012-11-21
ECSP088532A (es) 2008-08-29
IL192067A (en) 2010-12-30
CY1109320T1 (el) 2014-07-02
JO2549B1 (en) 2010-09-05
AU2006326551B2 (en) 2012-06-07
CR9993A (es) 2008-09-23
EP1965768A2 (en) 2008-09-10
KR20080074180A (ko) 2008-08-12
US8933097B2 (en) 2015-01-13
RU2008128418A (ru) 2010-01-20
BRPI0619895A2 (pt) 2011-10-25
NO20082904L (no) 2008-09-10
AR058323A1 (es) 2008-01-30
HK1123197A1 (en) 2009-06-12
MA30152B1 (fr) 2009-01-02
HRP20090411T1 (hr) 2010-01-31
PL1965768T3 (pl) 2009-11-30
EG25866A (en) 2012-09-12
AU2006326551A1 (en) 2007-06-21
EP1965768B1 (en) 2009-05-13
NO339877B1 (no) 2017-02-13

Similar Documents

Publication Publication Date Title
US8933097B2 (en) Fexofenadine suspension formulation
US6150366A (en) Ziprasidone formulations
JP6770754B2 (ja) 輸液又は注射として及び輸液濃縮物の静脈内投与のためのレボシメンダンの改善された調製物
SK1722002A3 (en) Beta-carboline drug products
CN112220748A (zh) 地氯雷他定口服液制剂及其制备方法
HK1123197B (en) Fexofenadine suspension formulation
US20220323358A1 (en) Powder for oral suspension containing tadalafil
KR102940722B1 (ko) 생체 이용률이 개선된 페노피브레이트를 포함하는 약학 조성물
US20250325517A1 (en) Oral dosage forms of elraglusib
CN121081383A (zh) 布瑞哌唑混悬液及其用途
HK1024184B (en) Ziprasidone formulations

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20171012

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20180918

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191015

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191015